KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for BeOne Medicines (ONC) over the last 11 years, with Q3 2025 value amounting to $37.3 million.

  • BeOne Medicines' Depreciation & Amortization (CF) fell 4770.24% to $37.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $155.9 million, marking a year-over-year increase of 730.24%. This contributed to the annual value of $171.8 million for FY2024, which is 9590.76% up from last year.
  • Latest data reveals that BeOne Medicines reported Depreciation & Amortization (CF) of $37.3 million as of Q3 2025, which was down 4770.24% from $35.6 million recorded in Q2 2025.
  • In the past 5 years, BeOne Medicines' Depreciation & Amortization (CF) ranged from a high of $71.3 million in Q3 2024 and a low of $9.6 million during Q1 2021
  • Its 5-year average for Depreciation & Amortization (CF) is $25.2 million, with a median of $21.5 million in 2023.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first soared by 23143.65% in 2024, then plummeted by 4770.24% in 2025.
  • Over the past 5 years, BeOne Medicines' Depreciation & Amortization (CF) (Quarter) stood at $13.1 million in 2021, then surged by 37.31% to $18.0 million in 2022, then skyrocketed by 32.21% to $23.8 million in 2023, then soared by 110.95% to $50.2 million in 2024, then fell by 25.8% to $37.3 million in 2025.
  • Its Depreciation & Amortization (CF) was $37.3 million in Q3 2025, compared to $35.6 million in Q2 2025 and $32.8 million in Q1 2025.